Streetwise
Lauren Rudd
Sunday, August 25, 2013
Tips Are For Horse Races
Whenever I mention that I write about investing in stocks,
the response is not only predictable but can be divided into three distinct
categories. The first is, “Wonderful, do you have any hot tips?” However, I must
point out that there is often a tone of sarcasm nowadays from those who left
Wall Street after the dotcom era and headed directly into real estate since you
never lose money investing in brick and mortar.
In the past I tried to educate these misguided souls, thereby
leaving the hot tip emporium to the horse racing crowd. However, to utilize an
equine metaphor, you can lead a horse to water but you cannot make him drink.
Therefore, over time I have learned to shorten my response to a single
word...no.
The second category of individuals look at me askance, their
faces blanching as they put forth a diatribe on how nobody makes money on Wall
Street and how whenever they have taken somebody’s investment advice they lost
money and am I aware of what has happened on Wall Street recently?
No sir, their money is staying right where it is, in a
government guaranteed certificate of deposit or savings account. Tactfully, I do
not point out that after taxes and inflation, it is probably also generating a
negative return.
Finally, there are the well intentioned who blindly follow
the advice of someone they barely know and invest in companies or mutual funds
they know little about except for some glossy pictures in a marketing brochure
or annual report. The hype is high, as are the commissions and fees, but not the
performance.
Many of you research an automobile down to the tire size, or
know the number ice cubes per hour a new refrigerator puts out, yet when it
comes to investing your hard earned money you pass up readily discernible and
potentially rewarding blue chip investment opportunities. Moreover, the total
commission, there are no fees, is generally less than the price of lunch at
McDonald’s.
Meanwhile, you still have to deal with the current investment
environment. Therefore, you might begin by ignoring the perturbations on Wall
Street, while acknowledging that quality investment opportunities remain
plentiful. A good example is Varian Medical Systems (VAR), a company that
manufacturers cancer therapy systems. The demographic of an aging population
plays a major role here.
When I last talked about Varian a year ago, my earnings
estimate for the 2011 fiscal year ended September 30 was $3.48 per share, with a
12-month target price on the stock of $61, for an annualized capital gain of 15
percent. So how well did Varian do?
Earnings for the year came in at $3.44 per share, while the
shares recently closed at $59.68. Although earnings and share price were off
slightly from my forecast, last February or six months after I wrote about
Varian the shares were trading at $70.80.
Here is another excellent example of where the implementation
of a stop loss order could have protected your gains, while at the same time
enabling you to repurchase the shares, if you so desired, at about $53 per share
in mid-July of this year, thereby creating an additional return of 12.6 percent
from that point until the present.
In doing so you are not morphing into a day trader addicted
to charts rather than utilizing fundamental analysis with a long-term investment
horizon. Rather you are simply modifying your position when the market has
either over-priced or underpriced a company’s underlying value. This is no
different from what Warren Buffett has repeatedly addressed as being the key to
successful investing.
So how does Varian look going forward? The Company reported
net earnings of $0.96 per share for the third quarter ended June 30, up 16
percent from $0.83 in the year-ago quarter.
Revenues were $705 million, an increase of 9 percent over the year-ago
quarter.
The company ended the third quarter with $633 million in cash
and cash equivalents and $175 million of debt. In its forward looking guidance,
management is forecasting an increase in 2012 revenues of 8 percent, with
earnings per share up by 8 to 9 percent.
The intrinsic value of the shares, using a discounted earnings model with a
growth rate of 12.58 percent and a discount rate of 15 percent is $84. The more
conservative free cash flow the firm approach yields an intrinsic value of $122
per share. My earnings estimate for fiscal 2012 is $3.75 per share, with a
12-month target price on the stock of $68, for an annualized capital gain of 15
percent.